Xenon Pharmaceuticals (XENE) News Today $38.52 -1.10 (-2.78%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Assenagon Asset Management S.A. Has $9.35 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Assenagon Asset Management S.A. grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 12.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 238,522 shares of the biopharmaceutical company's sJanuary 19 at 3:25 AM | marketbeat.comXenon Pharmaceuticals announces executive changesJanuary 17 at 5:13 PM | msn.comBarclays PLC Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Barclays PLC grew its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1,275.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 14,993 shares of the biopharmaceutical company's stock after buying an additional 13,903 shares during the peJanuary 17 at 3:10 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Rating of "Buy" from BrokeragesXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has earned a consensus recommendation of "Buy" from the eight analysts that are covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the coJanuary 16, 2025 | marketbeat.comXenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy PotentialJanuary 16, 2025 | seekingalpha.comXenon Pharmaceuticals outlines key corporate milestone opportunities for 2025January 15, 2025 | markets.businessinsider.comXenon Outlines Key Corporate Milestone Opportunities for 2025January 13, 2025 | globenewswire.comInvestors Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of some unusual options trading on Wednesday. Stock investors bought 4,063 put options on the company. This is an increase of 2,362% compared to the typical volume of 165 put options.January 9, 2025 | marketbeat.comXenon to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comJPMorgan Chase & Co. Buys 905,129 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)JPMorgan Chase & Co. raised its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1,263.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 976,783 shares of the biopharmaceutical company's stock afterJanuary 6, 2025 | marketbeat.comBarclays PLC Has $590,000 Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Barclays PLC boosted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1,275.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,993 shares of the biopharmaceutical comJanuary 2, 2025 | marketbeat.comState Street Corp Buys 32,701 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)State Street Corp raised its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 279,513 shares of the biopharmaceutical company's stock after purchasing an additioDecember 26, 2024 | marketbeat.comXenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw unusually large options trading activity on Wednesday. Investors acquired 4,063 put options on the company. This is an increase of 2,362% compared to the average daily volume of 165 put options.December 26, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from BrokeragesShares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have earned a consensus recommendation of "Buy" from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy reDecember 22, 2024 | marketbeat.comFranklin Resources Inc. Reduces Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Franklin Resources Inc. decreased its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 2.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 565,915 shares of the biopharmaceutical company's stock after sellingDecember 20, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin Sells 18,709 SharesXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) CFO Sherry Aulin sold 18,709 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.December 19, 2024 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.1% - Here's What HappenedXenon Pharmaceuticals (NASDAQ:XENE) Shares Down 3.1% - What's Next?December 19, 2024 | marketbeat.comLord Abbett & CO. LLC Has $6.85 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Lord Abbett & CO. LLC trimmed its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 8.4% in the third quarter, according to its most recent filing with the SEC. The firm owned 173,985 shares of the biopharmaceutical company's stock after selling 16,048 shares during thDecember 17, 2024 | marketbeat.comPromising Efficacy and Tolerability: Douglas Tsao’s Buy Rating on Xenon Pharmaceuticals’ AzetukalnerDecember 12, 2024 | markets.businessinsider.comXenon Pharmaceuticals (NASDAQ:XENE) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Thursday.December 12, 2024 | marketbeat.comStock Traders Buy Large Volume of Xenon Pharmaceuticals Put Options (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw some unusual options trading activity on Wednesday. Traders bought 4,063 put options on the company. This is an increase of 2,362% compared to the typical daily volume of 165 put options.December 12, 2024 | marketbeat.comPromising Phase IIb Data and Pipeline Advancements Drive Buy Rating for XenonDecember 10, 2024 | markets.businessinsider.comWellington Management Group LLP Has $151.32 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Wellington Management Group LLP lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 0.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,843,447 shares ofDecember 10, 2024 | marketbeat.comTwo Sigma Advisers LP Has $10.78 Million Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Two Sigma Advisers LP increased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 31.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 273,700 shares of the biopharmaceutiDecember 10, 2024 | marketbeat.comPoint72 Asset Management L.P. Reduces Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Point72 Asset Management L.P. trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 20.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 383,290 shares of the biopharmaceuticalDecember 7, 2024 | marketbeat.comXenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024December 6, 2024 | globenewswire.comJanus Henderson Group PLC Has $100.51 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Janus Henderson Group PLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 144.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,552,392 shares of the biophaDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Sells 17,632 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Parkman Healthcare Partners LLC lessened its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 8.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 191,658 shares of the biopharmaceutical company's stock afteDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Erste Asset Management GmbH acquired a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 50,000 shares of the biopharmaceutical compDecember 4, 2024 | marketbeat.comWalleye Capital LLC Takes Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Walleye Capital LLC purchased a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 104,960 shares of the biopharmaceuDecember 2, 2024 | marketbeat.comFmr LLC Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Fmr LLC grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 2.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,917,684 shares of the biopharmacDecember 2, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Holdings Lifted by Braidwell LPBraidwell LP lifted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 5.7% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,707,255 shares of the biopharmaceutical company's stock after bNovember 29, 2024 | marketbeat.comVestal Point Capital LP Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Vestal Point Capital LP lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 57.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 825,000 shares of the biopharmaceutical company's stockNovember 29, 2024 | marketbeat.comAlly Bridge Group NY LLC Acquires 42,422 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Ally Bridge Group NY LLC raised its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 25.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 211,791 shares of the biopharmaceutical company's stock after buying an aNovember 28, 2024 | marketbeat.comTraders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw some unusual options trading activity on Wednesday. Traders bought 4,063 put options on the company. This represents an increase of 2,362% compared to the typical volume of 165 put options.November 28, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Average Recommendation of "Buy" from AnalystsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has been given a consensus recommendation of "Buy" by the twelve ratings firms that are covering the company, Marketbeat Ratings reports. Eleven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recNovember 27, 2024 | marketbeat.comLoomis Sayles & Co. L P Buys 46,964 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Loomis Sayles & Co. L P grew its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 7.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 707,222 shares of the biopharmaceuticalNovember 26, 2024 | marketbeat.comXenon Pharmaceuticals Inc. Announces Multiple Poster Presentations at AES 2024 Featuring New Data on Azetukalner and Nav1.1 ProgramNovember 25, 2024 | quiverquant.comXenon to Showcase New Long-Term Azetukalner Data at AES 2024November 25, 2024 | globenewswire.comWestfield Capital Management Co. LP Buys 26,054 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Westfield Capital Management Co. LP grew its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 669,600 shares of tNovember 25, 2024 | marketbeat.comXenon Pharmaceuticals director sells $200,946 in stockNovember 24, 2024 | investing.comBNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $17.29 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 439,074 shares of thNovember 24, 2024 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gary Patou Sells 4,891 SharesNovember 23, 2024 | insidertrades.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Sells $200,922.28 in StockXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) Director Gary Patou sold 4,891 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total transaction of $200,922.28. Following the sale, the director now directly owns 23,573 shares of the company's stock, valued at approximately $968,378.84. This represents a 17.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.November 22, 2024 | marketbeat.comFirst Turn Management LLC Sells 14,658 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)First Turn Management LLC trimmed its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 4.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 325,218 sNovember 19, 2024 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down - Here's What HappenedXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down - Here's What HappenedNovember 18, 2024 | marketbeat.comFY2024 EPS Forecast for Xenon Pharmaceuticals Cut by AnalystXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Cantor Fitzgerald reduced their FY2024 EPS estimates for shares of Xenon Pharmaceuticals in a research report issued on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the biopharNovember 18, 2024 | marketbeat.comEquities Analysts Issue Forecasts for XENE FY2024 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities research analysts at HC Wainwright decreased their FY2024 EPS estimates for Xenon Pharmaceuticals in a research note issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical compaNovember 18, 2024 | marketbeat.comPromising Prospects and Strategic Advances Drive Buy Rating for Xenon PharmaceuticalsNovember 15, 2024 | markets.businessinsider.comQ1 Earnings Forecast for XENE Issued By HC WainwrightXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a report issued on Wednesday, November 13th. HC Wainwright analyst D. Tsao expects that the biopharmaceuticalNovember 15, 2024 | marketbeat.com Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address XENE Media Mentions By Week XENE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XENE News Sentiment▼1.040.44▲Average Medical News Sentiment XENE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XENE Articles This Week▼64▲XENE Articles Average Week Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Catalent News Sarepta Therapeutics News Vaxcyte News Qiagen News Roivant Sciences News Ascendis Pharma A/S News Blueprint Medicines News Revolution Medicines News BridgeBio Pharma News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XENE) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
